Other Events ·
Sanofi announced the discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in…
SNYSanofi
Sanofi announced the discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis. The company decided not to submit the drug for global regulatory reviews because the current efficacy and safety evidence does not suggest it would provide a meaningful improvement over existing standards of care. Sanofi is not amending its full-year 2026 guidance due to this decision. Additionally, the company is evolving its Executive Committee effective September 1, 2026, to support its next strategic chapter. Sanofi is a biopharma company that develops medicines and vaccines.